Neurocrine Biosciences, Inc. (NASDAQ:NBIX) had its price objective decreased by equities researchers at Leerink Swann from $68.00 to $66.00 in a note issued to investors on Thursday. The brokerage currently has an “outperform” rating on the stock. Leerink Swann’s price target would indicate a potential upside of 42.80% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $55.00 price target on shares of Neurocrine Biosciences in a research report on Friday, February 10th. Jefferies Group LLC upped their price target on Neurocrine Biosciences from $65.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, May 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target (down previously from $62.00) on shares of Neurocrine Biosciences in a research report on Wednesday. Bank of America Corp began coverage on Neurocrine Biosciences in a research report on Friday, May 5th. They set a “buy” rating and a $70.00 price target on the stock. Finally, JPMorgan Chase & Co. set a $60.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, April 12th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $67.75.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) traded down 4.99% on Thursday, reaching $46.22. The company’s stock had a trading volume of 1,626,169 shares. The firm has a 50 day moving average of $51.55 and a 200 day moving average of $45.71. The firm’s market cap is $4.07 billion. Neurocrine Biosciences has a 12 month low of $37.35 and a 12 month high of $55.38.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.23. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. Analysts anticipate that Neurocrine Biosciences will post ($2.46) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Neurocrine Biosciences, Inc. (NBIX) PT Lowered to $66.00 at Leerink Swann” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/05/27/neurocrine-biosciences-inc-nbix-pt-lowered-to-66-00-at-leerink-swann.html.

In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 21,739 shares of the company’s stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $53.23, for a total value of $1,157,166.97. Following the transaction, the chief executive officer now directly owns 354,346 shares in the company, valued at approximately $18,861,837.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Malcolm Lloyd-Smith sold 9,960 shares of the company’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $53.63, for a total value of $534,154.80. Following the completion of the transaction, the insider now owns 17,997 shares in the company, valued at $965,179.11. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 104,360 shares of company stock worth $5,501,889. 4.80% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in NBIX. Independent Portfolio Consultants Inc. acquired a new position in shares of Neurocrine Biosciences during the first quarter worth $106,000. First Mercantile Trust Co. raised its position in shares of Neurocrine Biosciences by 22.2% in the first quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after buying an additional 560 shares in the last quarter. Capstone Asset Management Co. acquired a new position in shares of Neurocrine Biosciences during the first quarter worth $214,000. Grandfield & Dodd LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter worth $230,000. Finally, Opus Point Partners Management LLC raised its position in shares of Neurocrine Biosciences by 50.9% in the fourth quarter. Opus Point Partners Management LLC now owns 6,137 shares of the company’s stock worth $238,000 after buying an additional 2,069 shares in the last quarter. Institutional investors and hedge funds own 97.60% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

12 Month Chart for NASDAQ:NBIX

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.